These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 10690631

  • 1. Studies on p53 immunolocalisation in breast cancer and its prognostic significance.
    Meenakshi A, Manoharan V.
    Hum Antibodies; 1999; 9(3):171-6. PubMed ID: 10690631
    [Abstract] [Full Text] [Related]

  • 2. Cysteine proteinase inhibitor cystatin A in breast cancer.
    Kuopio T, Kankaanranta A, Jalava P, Kronqvist P, Kotkansalo T, Weber E, Collan Y.
    Cancer Res; 1998 Feb 01; 58(3):432-6. PubMed ID: 9458085
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S.
    J Am Coll Surg; 2004 Jan 01; 198(1):83-90. PubMed ID: 14698315
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
    Beck T, Weller EE, Weikel W, Brumm C, Wilkens C, Knapstein PG.
    Gynecol Oncol; 1995 Apr 01; 57(1):96-104. PubMed ID: 7705708
    [Abstract] [Full Text] [Related]

  • 7. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer.
    Elledge RM, Clark GM, Fuqua SA, Yu YY, Allred DC.
    Cancer Res; 1994 Jul 15; 54(14):3752-7. PubMed ID: 8033095
    [Abstract] [Full Text] [Related]

  • 8. p53 protein expression in human breast carcinoma: lack of prognostic potential for recurrence of the disease.
    Katoh A, Breier S, Stemmler N, Specht S, Blanock K, D'Amico F.
    Anticancer Res; 1996 Jul 15; 16(3A):1301-4. PubMed ID: 8702254
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival.
    Hanzal E, Gitsch G, Kohlberger P, Dadak C, Miechowiecka N, Breitenecker G.
    Anticancer Res; 1992 Jul 15; 12(6B):2325-9. PubMed ID: 1295480
    [Abstract] [Full Text] [Related]

  • 12. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
    Gao RJ, Bao HZ, Yang Q, Cong Q, Song JN, Wang L.
    Breast Cancer Res Treat; 2005 Sep 15; 93(2):111-5. PubMed ID: 16187230
    [Abstract] [Full Text] [Related]

  • 13. Immunohistochemical localisation of tenascin in invasive ductal carcinoma of the breast.
    Tökés AM, Hortoványi E, Csordás G, Kulka J, Mózes G, Hatalyák A, Kádár A.
    Anticancer Res; 1999 Sep 15; 19(1A):175-9. PubMed ID: 10226540
    [Abstract] [Full Text] [Related]

  • 14. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
    Huober J, Sprenger H, Costa SD, Zentgraf H, Schmid H, Kaufmann M, Bastert G.
    Zentralbl Gynakol; 1996 Sep 15; 118(10):560-4. PubMed ID: 8999710
    [Abstract] [Full Text] [Related]

  • 15. Expression of p53 protein in infiltrating and in-situ breast carcinomas.
    Walker RA, Dearing SJ, Lane DP, Varley JM.
    J Pathol; 1991 Nov 15; 165(3):203-11. PubMed ID: 1684809
    [Abstract] [Full Text] [Related]

  • 16. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
    Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D, Jacquemier J, Viens P.
    J Pathol; 2004 Mar 15; 202(3):265-73. PubMed ID: 14991891
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of p53 protein expression in breast carcinomas.
    Hurlimann J.
    Pathol Res Pract; 1993 Nov 15; 189(9):996-1003. PubMed ID: 8302733
    [Abstract] [Full Text] [Related]

  • 18. Prognostic factors and survival analysis of invasive ductal carcinoma of the breast in Bandung, Indonesia.
    Hernowo BS, Yukawa M, Asaka K, Fujimori T, Maeda S, Mukawi TY.
    Kobe J Med Sci; 1995 Aug 15; 41(4):95-112. PubMed ID: 8904161
    [No Abstract] [Full Text] [Related]

  • 19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 20. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.
    Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y, Iwase H.
    Breast Cancer Res; 2006 Apr 12; 8(4):R48. PubMed ID: 16869955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.